Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

RemeGen Reports Positive Results from Confirmatory Trial of Lupus Therapy

publication date: Sep 21, 2022

RemeGen, a Yantai biotech, reported positive preliminary results from a confirmatory China Phase III trial of Teliacicept, a therapy for systemic lupus erythematosus (SLE). Teliacicept, a novel fusion protein, is being tested in multiple autoimmune diseases. The candidate targets two cell-signaling molecules that are critical for B-lymphocyte development: B-cell lymphocyte stimulator (BLyS), and a proliferation inducing ligand (APRIL) that reduces B-cell mediated autoimmune responses. In March 2021, Teliacicept was granted conditional marketing approval in China for SLE. More details....

Stock Symbols: (HK: 9995; SHA: 688331)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China